Under the terms of the agreement, NiKem Research will make its integrated platform available to Neurotune, including medicinal, parallel and analytical chemistry, exploratory ADMET profiling and in vivo PK. The collaboration aims to design, synthesize and optimize compounds against Neurotune proprietary target neurotrypsin.
Financial terms of the agreement were not disclosed.
In collaborating with NiKem Research, Neurotune adds to its own expertise the knowledge and the technologies for the fast optimization of meaningful leads.
NiKem Research understands that biology-oriented, innovation rich young Biotech companies represent a significant market opportunity for integrated, medchem-driven drug discovery CROs. NiKem Research is flexible enough to accommodate the project needs and the financial constraints of small Biotechs, and is committed to deliver high quality preclinical candidates.
In particular, NiKem Research is delighted to work with Neurotune on an exciting and innovative project, and looks forward to a long and fruitful collaboration between the two companies.